What changed: Early HER2-positive breast cancer
Every dated change on the records linked to Early HER2-positive breast cancer, newest first: approvals and regulatory steps on its medicines, trials that reported, guideline versions, milestones, and when this page itself was checked. Dates come from the records; none is inferred. Orientation, not medical advice.
Trial result10Milestone10This record1
September 2026 · 1
2025 · 3
2024 · 2
2019 · 2
2018 · 4
- 2018Trial resultKATHERINEKATHERINE reported
iDFS HR 0.
- 2018Trial resultKRISTINEKRISTINE reported
Pathological complete response 44.
- 2018Trial resultTRAIN-2TRAIN-2 reported
Pathological complete response 67% without anthracycline vs 68% with; 3-year event-free survival 93.
- 2018MilestoneKATHERINEKATHERINE, TRAIN-2 and KRISTINE
A milestone in how this cancer is treated.
2017 · 2
2015 · 1
2013 · 1
2012 · 1
2005 · 2
- 2005Trial resultHERA, NSABP B-31 & NCCTG N9831 (adjuvant trastuzumab)HERA, NSABP B-31 & NCCTG N9831 (adjuvant trastuzumab) reported
B-31/N9831 10-year OS 84% vs 75.
- 2005MilestoneHERA, NSABP B-31 & NCCTG N9831 (adjuvant trastuzumab)HERA, NSABP B-31 and N9831: a year of adjuvant trastuzumab
A milestone in how this cancer is treated.